NCCN Guidelines for Patients® | Melanoma - page 73

73
NCCN Guidelines for Patients
®
: Melanoma
Version 1.2013
Par t 1
Par t 2
Par t 3
Par t 4
Par t 5
Par t 6
Par t 7
Par t 8
Par t 9
Part 6: A step-by-step treatment guide
Definitions:
Gene:
A set of coded
instructions in cells needed
for making and controlling
cells
Organ reserve:
How well
organs are working
Performance status:
A
rating of one’s ability to do
daily activities
Side effect:
An unplanned
physical or emotional
response to treatment
Systemic therapy:
Drugs
used to treat cancer cells
throughout the body
!
See Part 4 on page
34 for more treatment
details and definitions.
Table 5. Systemic therapy for advanced or metastatic melanoma
Preferred regimens
Ipilimumab
Vemurafenib
Clinical trial
High-dose interleukin-2
Other regimens
Dacarbazine
Temozolomide
Imatinib (for
c-kit
mutated tumors)
Paclitaxel
Paclitaxel and carboplatin
Dacarbazine- or temozolomide-based combination chemotherapy/
biochemotherapy including cisplatin and vinblastine ± interleukin-2 or
interferon alfa
Acronyms:
REMS =
Risk evaluation
and mitigation strategy
1...,63,64,65,66,67,68,69,70,71,72 74,75,76,77,78,79,80,81,82,83,...108
Powered by FlippingBook